ProCE Banner Activity

Retrospective Analysis of Immunotherapy Retreatment Following Immune-Related AEs in NSCLC Pts Treated With Anti–PD-(L)1 Therapy

Slideset Download
Conference Coverage
One half of patients with irAE-related dose interruptions experienced recurrent or new irAEs during immunotherapy retreatment.

Released: June 05, 2017

Expiration: June 04, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology